Possible rivaroxaban failure during the postpartum period

Pharmacotherapy

Volumn 35, Issue 11, 2015, Pages e164-e168

  Rudd, Kelly M ^a   Winans, Amanda R McFee ^a   Panneerselvam, Narmadha ^a  

^a BASSETT MEDICAL CENTER   (United States)

Author keywords

anticoagulation; direct acting oral anticoagulant; pharmacokinetics; postpartum; pregnancy

Indexed keywords

ANTICOAGULANT AGENT; ANTITHYROID AGENT; ENOXAPARIN; HEPARIN; IBUPROFEN; RIVAROXABAN; VITAMIN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BACKACHE; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FOOT PARESTHESIA; HAND PARESTHESIA; HEADACHE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTHYROIDISM; LEG CRAMP; LUNG EMBOLISM; MEDICAL HISTORY; MORNING DOSAGE; PARESTHESIA; PATIENT COMPLIANCE; POSTPARTUM HEMORRHAGE; PUERPERIUM; TACHYCARDIA; THORAX PAIN; TREATMENT FAILURE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; ORAL DRUG ADMINISTRATION; PULMONARY EMBOLISM; RECURRENT DISEASE;

ADMINISTRATION, ORAL; ADULT; FACTOR XA INHIBITORS; FEMALE; HUMANS; POSTPARTUM PERIOD; PULMONARY EMBOLISM; RECURRENCE; RIVAROXABAN; TREATMENT FAILURE;

EID: 84948124331     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1662     Document Type: Article

References (15)

1. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III,. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697-706.
2. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ,. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632-7.
3. James AH, Tapson VF, Goldhaber SZ,. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol 2005; 193: 216-9.
4. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO,. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e691S-736S.
5. Macklon NS, Greer IA, Bowman AW,. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 1997; 104: 191-7.
6. Brenner B,. Haemostatic changes in pregnancy. Thromb Res 2004; 114: 409-14.
7. Eichinger S, Weltermann A, Philipp K, et al., Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost 1999; 82: 1232-6.
8. Hague WM, North RA, Gallus AS, et al., Anticoagulation in pregnancy and the puerperium. Med J Aust 2001; 175: 258-63.
9. Duhl AJ, Paidas MJ, Ural SH, et al., Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197 (457): e1-21.
10. Anderson GD,. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008.
11. Dawes M, Chowienczyk PJ,. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001; 15: 819-26.
12. Rudd KM, Phillips EL,. New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. Thrombosis 2013; 2013: 973710.
13. Janssen Pharmaceuticals. Xarelto (rivaroxaban) package insert. Titusville, NJ: Janssen Pharmaceuticals; 2015.
14. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS,. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62.
15. Bauersachs R, Berkowitz SD, Brenner B, et al., Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.